Kalceks, a Latvian pharmaceutical company, continues its international expansion with the signing of a long-term agreement with the German pharmaceutical company Fresenius Kabi on distribution of its drugs in the Belgian market.
“Over several years, we had built a sizable registered medicines portfolio in Belgium. Commercialisation of two products is a result of intensive and persistent teamwork that will allow us to strengthen our position in a dynamic and strategically important European Union market,” explains Kaspars Kuprevičs, Chairman of the Board at Kalceks.
The collaboration with a subsidiary company of Fresenius, one of the leading healthcare groups globally, foresees distribution of two of Latvian pharmaceutical company Kalceks’s hospital medications—Magnesium sulphate and Droperidol injections —in the Belgian market.
“Fresenius Kabi is very pleased to enter into this partnership with Kalceks. Synergy is and remains an indispensable aspect in all business sectors and we are therefore highly motivated to be able to further expand our portfolio on the Belgian market thanks to the launch of Droperidol and Magnesium Sulfate. We look forward to a successful and instructive collaboration,” indicates Miranda Heining, General Manager Fresenius Kabi Belgium & The Netherlands.
In a relatively short period of time, the company has managed to conclude agreements with global pharmaceutical firms on distribution of Kalceks’s products in the European Union—Germany, Belgium, the Netherlands, Spain, France, Poland, which has produced a positive effect on its export indicators. Evaluating the achieved results, Kuprevičs emphasizes the set strategy, thanks to which the company has persistently launched new products and penetrated new markets.
“With every new cooperation, we successfully pursue the old traditions of pharmacy. Belgium also boasts a long history of pharmacy, as evidenced by the presence of many local firms in the market as well as all the biggest companies in the world. This, in fact, was one of the last EU countries where Kalceks’s products had not been commercialised yet. We have managed to conquer a new market, and now we are looking to expand our range of registered medications in other countries to increase our competitiveness on the international scale,” emphasizes Kaspars Kuprevičs, Chairman of the Board at Kalceks.
Kalceks exports its medications to 98 countries worldwide. The key markets for its products are the Western European countries: Spain, the UK, France, and the Netherlands, as well as Israel in the Middle East region. At present, around 60% of the company’s products are exported to European countries. Medications produced by Kalceks are also available outside Europe—in North America, South America, Africa, Asia, and Australia.
Kalceks AS is one of the oldest pharmaceutical companies in the Baltics, specializing in the development of generic medicine—from research to manufacturing to distribution—mainly for hospitals. The company's most demanded products are emergency medicines, with specialization in the CNS and cardiovascular medications therapeutic groups.